Peripheral blood CD34+ cell count reliably predicts autograft yield

Chapple, J. Paul; Prince, H. Miles; Quinn, Michael; Bertoncello, Ivan; Juneja, Surender; Wolf, M.; Januszewicz, Henry; Brettell, M; Gardyn, Joseph; Seymour, Colin; Venter, Deon J.

doi:10.1038/sj.bmt.1701308

Cited by 49 publications

(45 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequently, it has been shown that mononuclear cell counts correlate poorly with CD34 þ cells; hence, the true number of infused stem cells in early studies is not well known. 18,19 At the time of earlier studies, fluoroquinolone antibiotic prophylaxis was not available. Ciprofloxacin was not approved until 1987, and triazole antifungal antibiotics, such as ketoconazole and fluconazole, were not introduced until 1990.…”

Section: Discussionmentioning

confidence: 99%

SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization

Gertz¹,

Gastineau²,

Lacy³

et al. 2010

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization

Gertz¹,

Gastineau²,

Lacy³

et al. 2010

Bone Marrow Transplant

View full text Add to dashboard Cite

“…Each send-out, from Spring 1996 to Autumn 2004 was chronologically assigned with a unique number (i.e., [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16]. In this way, we analyzed any effect of the EQA program on the results of the participants as a function of time.…”

Section: Data Processing and Parameter Classificationmentioning

confidence: 99%

“…This emphasizes the need for an adequate prediction of engraftment potency of HSCs in patients after receiving myeloablative therapy followed by HSC transplantation (8)(9)(10)(11). Furthermore, enumeration of CD34þ cells has been shown to be useful in con-siderations of peripheral blood stem cell harvesting (12)(13)(14)(15)(16) and in comparing the efficacy of various PB stem cell mobilization strategies (reviewed by Fruehauf and Kessinger and Sharp) (17,18). Furthermore, CD34þ cell enumeration is useful for monitoring the stem cell yield during graft manipulations, such as immunomagnetic selections, ex vivo expansion, or genetic modifications of HSCs.…”

mentioning

confidence: 99%

Flow cytometric CD34+ stem cell enumeration: Lessons from nine years' external quality assessment within the Benelux countries

Levering

Preijers

Wieringen

et al. 2007

Cytometry Part B Clinical

View full text Add to dashboard Cite

Background: A biannual external quality assurance (EQA) scheme for flow cytometric CD34+ haematopoietic stem cell enumeration has been operational in the Benelux countries since 1996. In an evaluation of the results of 16 send-outs, we studied the effects of the methods used on assay outcome and whether or not this exercise was effective in reducing between-laboratory variation.Methods: Data were analyzed using robust multivariate regression. This approach is relatively insensitive to outliers and is used to assess the effect of methodological aspects of CD34+ cell counting on the bias and variability.Results: Five variables were associated with significant bias of absolute CD34+ cell counts: (i) unique laboratory number (ULN), (ii) gating strategy; (iii) CD34 mAb fluorochrome; (iv) type of flow cytometer, and (v) method of sample preparation. In addition, ULN and platform methodology (i.e., single vs. dual) contributed significantly to the variability of this assay. Overall, the variability in results of CD34+ cell enumeration has declined with time; in particular, after a practical workshop in which participants were trained to use the ''single platform ISHAGE protocol.'' Conclusions: Between-laboratory variation in CD34+ cell enumeration can be reduced by standardization of methodologies between centres. Our approach, i.e., EQA with targeted training and feedback in response to reported results, has been successful in reducing the variability of CD34+ cell enumeration between participants. q 2007 Clinical Cytometry Society

show abstract

“…Flow cytometric enumeration of CD34 þ cells provides a rapid means of measuring this clinically useful surrogate marker of graft adequacy in all sources of HSCs and most transplant centers now determine graft adequacy based on the number of CD34 þ cells/Kg of patient body weight. In addition to determining yield, the number of CD34 þ cells mobilized to the peripheral blood is also a predictor of the success of apheresis (5) and can be used to monitor, ''on-line,'' the yield of CD34 þ cells (6). Although simple flow methods for counting CD34 þ cells date back to the late 1980's (7-13), a standardized multi-parameter protocol that was based on the structural characteristics of the CD34 molecule and the epitopes detected by various CD34 monoclonal antibodies did not emerge until 1994 (14).…”

mentioning

confidence: 99%

ISHAGE protocol: Are we doing it correctly?

Whitby

Fletcher

et al. 2011

Cytometry Part B Clinical

View full text Add to dashboard Cite

Background: Flow cytometric CD341 stem cell enumeration is routinely performed to optimize timing of peripheral blood stem cell collections and assess engraftment capability of the apheresis product. While a number of different flow methodologies have been described, the highly standardized ISHAGE protocol is currently the most widely employed, with 204/255 (81%) international participants in the UK NEQAS CD341 stem cell enumeration program indicating their use of this method. Recently, two laboratories were identified as persistent poor performers, a fact attributed to incorrect ISHAGE protocol usage/ setup. This prompted UK NEQAS to question whether other laboratories were making similar errors and, if so, how this might affect individual EQA performance.Methods and Results: In send out 0801, where two stabilized samples were issued, the EQA center surveyed 255 participants with flow analysis data and subsequent results collected. One hundred and ninety-six laboratories returned results with 103 returning dot plots. Eighty-three out of one hundred and three stated that they used the ISHAGE protocol gating strategy but 43% (36/83) were incorrectly setup. Analysis of the data showed those incorrectly using single platform ISHAGE gating strategy were twice as likely to fail an EQA exercise compared to those using the protocol correctly. This failure rate increased two fold when incorrect ISHAGE protocol was used in a dual platform setting.Conclusion: This study suggests a widespread fundamental lack of understanding of the ISHAGE protocol and the need to deploy it correctly, potentially having significant clinical implications and highlights the need to monitor participants rigorously in their deployment of the ISHAGE protocol. It is hoped that once these findings have been disseminated, performance can be improved. V C 2011 International Clinical

show abstract

Peripheral blood CD34+ cell count reliably predicts autograft yield

Abstract: Summary:A reliable measure to predict peripheral blood progenitor cell (PBPC) autograft CD34 + cell content is required to optimize the timing of PBPC collection. We prospectively examined the peripheral blood (

Cited by 49 publications

References 9 publications

SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization

SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization

Flow cytometric CD34+ stem cell enumeration: Lessons from nine years' external quality assessment within the Benelux countries

ISHAGE protocol: Are we doing it correctly?

Contact Info

Product

Resources

About